If the iPSCs you would like to access are currently listed as unavailable or
you would like information on local partners in USA, Australia, New Zealand or Japan who can support order and delivery,
please get in touch via
Contact@EBiSC.org.
PFIZi028-A
B212c7
iPSC line
A CLIP contains information about an iPSC line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the iPSC line.
The EBiSC Access and Use Agreement must be completed along with an individual
Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org
for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
iPSC Line |
|
| hPSCreg name | PFIZi028-A |
| Alternative name(s) |
B212c7
|
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines | No similar lines found. |
Provider |
|
| Depositor | Pfizer Limited - Pfizer (PFIZ) |
| Distributors |
EBiSC
|
External iPSC Databases |
|
| hPSCreg | PFIZi028-A |
| BioSamples | SAMEA104491452 |
| Cellosaurus | CVCL_VE76 |
| Wikidata | Q54947282 |
General iPSC Information |
|
| This EBiSC iPSC line can be used for: |
Yes
Research use: allowed
Clinical use: no
Commercial use: no
|
Donor Information#
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 5-9 |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA104491451 |
iPSC Derivation#
General |
|
| Source cell type |
A leukocyte with a single non-segmented nucleus in the mature form found in the circulatory pool of blood.
Synonyms
|
| Age of donor (at collection) | 5-9 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
iPSC Culture Conditions#
Latest released batch |
|
| Culture medium | mTeSR™1 |
| Passage method | EDTA |
| Surface coating | matrigel / Geltrex |
| O2 concentration | 21 |
| CO2 concentration | 5 |
| Temperature | 37 |
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Matrigel/Geltrex |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this iPSC line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this iPSC line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this iPSC line? | No |
iPSC Characterisation#
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| SSEA-1 |
No |
|
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
In vitro directed differentiation
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Sterility |
|
| Inoculation for microbiological growth | No Contaminants Detected |
| Mycoplasma | Not Detected |
| Viability | Viable post-cryopreservation |
Genotyping#
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
46, XX; Modal karyotype in 20 cells showed a normal female chromosome complement and banding pattern
Passage number: 12
Karyotyping method:
G-Banding
|
Other Genotyping (iPSC Line) |
|